Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: A Christmas Medical Conference

This article was originally published in Scrip

Executive Summary

It was the week before Christmas week, and all around were losing their heads. Probably not because the three wise men were en route to Bethlehem, but rather because three of the four horsemen of the apocalypse appeared to be arriving in their stead, if the savage sell-off in the stock market was anything to go by. The first driver of last week's stock market sell-off was the continued plummet in global commodity prices. It is difficult to derive a strong fundamental connection between oil and drug prices since cheaper oil reduces the cost of goods of the latter, but nevertheless there was a positive correlation last week.

You may also be interested in...

Stockwatch: Bluebird, Arrowhead And Short Memories

Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.

Stockwatch: Dynavax, CoLucid Investors Should Beware The Standard Of Care

Dynavax and CoLucid benefited from share price surges last week. But were investors throwing caution to the wind and overlooking the challenges and lessons presented by standard of care therapies? Meanwhile, bluebird bio’s stock soared again.

Stockwatch: Reading The Entrails Of Biotech Vaccine Development

As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts